127 related articles for article (PubMed ID: 38402864)
21. Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida.
Jones T; Howard H; Freeman-Costin K; Creighton A; Wisdom-Chambers K; Underhill-Blazey M
J Community Genet; 2021 Jul; 12(3):415-429. PubMed ID: 33555545
[TBL] [Abstract][Full Text] [Related]
22. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.
Lehmann LS; Weeks JC; Klar N; Garber JE
Genet Med; 2002; 4(5):346-52. PubMed ID: 12394347
[TBL] [Abstract][Full Text] [Related]
23. Barriers to cancer screening among Orthodox Jewish women.
Tkatch R; Hudson J; Katz A; Berry-Bobovski L; Vichich J; Eggly S; Penner LA; Albrecht TL
J Community Health; 2014 Dec; 39(6):1200-8. PubMed ID: 24845763
[TBL] [Abstract][Full Text] [Related]
24. Challenges of Pre- and Post-Test Counseling for Orthodox Jewish Individuals in the Premarital Phase.
Rose E; Schreiber-Agus N; Bajaj K; Klugman S; Goldwaser T
J Genet Couns; 2016 Feb; 25(1):18-24. PubMed ID: 26354339
[TBL] [Abstract][Full Text] [Related]
25. "I Took the Trouble to Make Inquiries, So I Refuse to Accept Your Instructions": Religious Authority and Vaccine Hesitancy Among Ultra-Orthodox Jewish Mothers in Israel.
Keshet Y; Popper-Giveon A
J Relig Health; 2021 Jun; 60(3):1992-2006. PubMed ID: 33389435
[TBL] [Abstract][Full Text] [Related]
26. Sexual Abuse in the Orthodox Jewish Community: A Literature Review.
Lusky-Weisrose E; Marmor A; Tener D
Trauma Violence Abuse; 2021 Dec; 22(5):1086-1103. PubMed ID: 32054401
[TBL] [Abstract][Full Text] [Related]
27. Improving access to mental health care in an Orthodox Jewish community: a critical reflection upon the accommodation of otherness.
McEvoy P; Williamson T; Kada R; Frazer D; Dhliwayo C; Gask L
BMC Health Serv Res; 2017 Aug; 17(1):557. PubMed ID: 28806946
[TBL] [Abstract][Full Text] [Related]
28. Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
Reisel D; Burnell M; Side L; Loggenberg K; Gessler S; Desai R; Sanderson S; Brady AF; Dorkins H; Wallis Y; Jacobs C; Legood R; Beller U; Tomlinson I; Wardle J; Menon U; Jacobs I; Manchanda R
BJOG; 2022 May; 129(6):959-968. PubMed ID: 34758513
[TBL] [Abstract][Full Text] [Related]
29. "Over-preoccupation with healthy food is perceived as worship of the body": Food, culture and beliefs in Ultra-Orthodox Jewish families.
Peles C; Shloim N; Rudolf MCJ
Appetite; 2021 Dec; 167():105621. PubMed ID: 34363899
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.
Rubinstein WS; Jiang H; Dellefave L; Rademaker AW
Genet Med; 2009 Sep; 11(9):629-39. PubMed ID: 19606050
[TBL] [Abstract][Full Text] [Related]
31. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
[TBL] [Abstract][Full Text] [Related]
33. Community attitudes towards a Jewish community BRCA1/2 testing program.
Cousens N; Kaur R; Meiser B; Andrews L
Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
[TBL] [Abstract][Full Text] [Related]
34. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
[TBL] [Abstract][Full Text] [Related]
35. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
36. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
[TBL] [Abstract][Full Text] [Related]
37. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
39. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
[TBL] [Abstract][Full Text] [Related]
40. A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of
Best AF; Tucker MA; Frone MN; Greene MH; Peters JA; Katki HA
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):293-302. PubMed ID: 30692095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
